Cargando…
Liver gene therapy by lentiviral vectors reverses anti-factor IX pre-existing immunity in haemophilic mice
A major complication of factor replacement therapy for haemophilia is the development of anti-factor neutralizing antibodies (inhibitors). Here we show that liver gene therapy by lentiviral vectors (LVs) expressing factor IX (FIX) strongly reduces pre-existing anti-FIX antibodies and eradicates FIX...
Autores principales: | Annoni, Andrea, Cantore, Alessio, Della Valle, Patrizia, Goudy, Kevin, Akbarpour, Mahzad, Russo, Fabio, Bartolaccini, Sara, D'Angelo, Armando, Roncarolo, Maria Grazia, Naldini, Luigi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3840485/ https://www.ncbi.nlm.nih.gov/pubmed/24106222 http://dx.doi.org/10.1002/emmm.201302857 |
Ejemplares similares
-
Modulation of immune responses in lentiviral vector-mediated gene transfer
por: Annoni, Andrea, et al.
Publicado: (2019) -
Genome editing for scalable production of alloantigen‐free lentiviral vectors for in vivo gene therapy
por: Milani, Michela, et al.
Publicado: (2017) -
WFH State‐of‐the‐art paper 2020: In vivo lentiviral vector gene therapy for haemophilia
por: Cantore, Alessio, et al.
Publicado: (2020) -
Manipulating Immune Tolerance with Micro-RNA Regulated Gene Therapy
por: Goudy, Kevin Scott, et al.
Publicado: (2011) -
Hepatocyte-Targeted Expression by Integrase-Defective Lentiviral Vectors Induces Antigen-Specific Tolerance in Mice with Low Genotoxic Risk
por: Mátrai, Janka, et al.
Publicado: (2011)